Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 684-692

  Merchante, Nicolás ^a   de los Santos Gil, Ignacio ^b   Merino, Dolores ^c   González Serrano, Mercedes ^d   Mira, José A ^a   Sanz Sanz, Jesús ^b   Fernández Fuertes, Elisa ^c   Ruiz Morales, Josefa ^d   Valle, José del ^a   Macías, Juan ^a   Moro, Antonio ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

HIV HCV co infection; HOMA; Insulin resistance; Pegylated interferon; SVR

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BODY MASS INDEX; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 61749102966     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.10.032     Document Type: Article

References (36)

1. Mocroft A., Brettle R., Kirk O., Blaxhult A., Parkin J.M., Antunes F., et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16 (2002) 1663-1671
2. Macias J., Melguizo I., Fernández-Rivera F.J., García-García J.A., Mira J.A., Ramos A.J., et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients on potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 21 (2002) 775-781
3. Salmon-Ceron D., Lewden C., Morlat P., Bevilacqua S., Jougla E., Bonnet F., et al. Liver disease as major cause of death among HIV-infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 42 (2005) 799-805
4. Pineda J.A., García-García J.A., Aguilar-Guisado M., Rios-Villegas M.J., Ruiz-Morales J., Rivero A., et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46 (2007) 622-630
5. Torriani F.J., Rodríguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
6. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri E., et al. Pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 292 (2004) 2839-2848
7. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
8. Laguno M., Murillas J., Blanco J.L., Martinez E., Miquel R., Sanchez-Tapias J.M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 18 (2004) F27-F36
9. Moreno L., Quereda C., Moreno A., Pérez-Elias J.M., Antela A., Casado J.L., et al. Pegylated interferon alfa 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 18 (2004) 67-73
10. Mira JA, Torre-Cisneros J, Merino D, Rios M, Collado A, Vergara S, et al. Efficacy of pegylated interferon plus ribavirin in HIV/HCV coinfection outside of well circumscribed clinical trials: the Andalusian multicenter study. In: 13th Conference on retroviruses and opportunistic infections, 22-25 February 2006, Denver, CO, USA. Abstract 861.
11. Zinkernagel A.S., von Wyl V., Ledergerber B., Rickenbach M., Furrer H., Battegay M., et al. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antivir Ther 11 (2006) 131-142
12. Romero-Gómez M., del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernández-Rodríguez C.M., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
13. D'Souza R., Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 (2005) 1509-1515
14. Conjeevaram H.S., Kleiner D.E., Everhart J.E., Hoofnagle J.H., Zacks S., Nezam H.A., et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45 (2007) 80-87
15. Palacios R., Merchante N., Macias J., González M., Castillo J., Ruiz J., et al. Incidence of and risk factors for insulin resistance in treatment-nai{dotless}̈ve HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 11 (2006) 529-535
16. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Tumer R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
17. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996) 289-293
18. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372-374
19. Ascaso J.F., Romero P., Real J.T., Priego A., Valdecabres C., and Carmena R. Quantification of insulin resistance with the values of basal insulin and HOMA index in a non-diabetic population. Med Clin (Barc) 117 (2001) 530-533
20. Ascaso J.F., Pardo S., Real J.T., Lorente R.I., Priego A., and Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 26 (2003) 3320-3325
21. Gopal K., Johnson T.C., Gopal S., Walfish A., Bang C.T., Suwandhi P., et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44 (2006) 335-340
22. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46 (2007) 403-410
23. Toyoda H., and Kumuda T. Cholesterol and lipoproteins levels as predictors of response to interferon for hepatitis C. [Letter]. Ann Intern Med 133 (2000) 921
24. Minuk G.Y., Weinstein S., and Kaita K.D. Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C. [Letter]. Ann Intern Med 132 (2000) 761-762
25. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Meigs J.B., et al. Population-based incidence rates and risks factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 53 (2004) 1782-1789
26. Charlton M.R., Pockros P.J., and Harrison S.A. Impact of obesity on treatment of chronic hepatitis C. Hepatology 43 (2006) 1177-1186
27. Rodríguez-Torres M., Govindarajan S., Solá R., Clumeck N., Lissen E., and Pessoa M. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy. A paired liver biopsy study. J Hepatol 48 (2008) 756-764
28. Opravil M., Sasadeusz J., Cooper D.A., Rockstroh J., Clumeck N., Clotet B., et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 47 (2008) 36-49
29. Pineda J.A., Mira J.A., de los Santos I., Valera-Bestard V., Rivero A., Merino D., et al. Influence of concomitant antiretroviral therapy on the rate of sustained virologic response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother 60 (2007) 1347-1354
30. Vispo E., Barreiro P., Pineda J.A., Mira J.A., Maida I., Martín-Carbonero L., et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 13 (2008) 429-437
31. Mira J.A., López-Cortés L.F., Barreiro P., Tural C., Torres-Tortosa M., de los Santos I., et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus-coinfected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 62 (2008) 1365-1373
32. Nasta P., Gatti F., Puoti M., Cologni G., Bergamaschi V., Borghi F., et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 22 (2008) 857-861
33. del Valle J., Mira J.A., de los Santos I., López-Cortés L.F., Merino D., Rivero A., et al. Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients. AIDS 22 (2008) 923-930
34. Monazahian M., Bohme I., Bonk S., Koch A., Scholz S., Grethe S., et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57 (1999) 223-229
35. Agnello V., Abel G., Elfahal M., Knight G.B., and Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96 (1999) 12766-12771
36. Enjoji M., Nakamuta M., Kinukawa N., Sugimoto R., Noguchi K., Tsuruta S., et al. Beta-lipoproteins influence the serum level of hepatitis C virus. Med Sci Monit 6 (2000) 841-844